IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+0.62%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$437M
AUM Growth
+$437M
(-22%)
Cap. Flow
-$126M
Cap. Flow
% of AUM
-28.81%
Top 10 Holdings %
Top 10 Hldgs %
31.44%
Holding
211
New
18
Increased
20
Reduced
105
Closed
27
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$21.9M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$11.5M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$9.39M |
| 4 |
Immatics
IMTX
|
$8.55M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
$6.15M |
Top Sells
| 1 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$48.9M |
| 2 |
Biogen
BIIB
|
$26.5M |
| 3 |
Alector
ALEC
|
$14.1M |
| 4 |
CRISPR Therapeutics
CRSP
|
$10.3M |
| 5 |
Annovis Bio
ANVS
|
$8.86M |
Sector Composition
| 1 | Healthcare | 97.59% |
| 2 | Consumer Staples | 0.77% |
| 3 | Technology | 0.56% |
| 4 | Financials | 0.17% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Acadia Pharmaceuticals
ACAD
$4.3B
| $4.68M | 0.33% |
281,765
+71,899
| +34% | +$1.19M |
|
|
BLU
27
DELISTED
BELLUS Health Inc.
BLU
| $4.57M | 0.32% |
744,616
-265,929
| -26% | -$1.63M |
|
28
Galapagos
GLPG
$2.05B
| $4.54M | 0.32% |
86,865
-113,135
| -57% | -$5.92M |
|
29
Iovance Biotherapeutics
IOVA
$792M
| $4.25M | 0.3% |
172,521
-2,479
| -1% | -$61.1K |
|
30
Seres Therapeutics
MCRB
$167M
| $4.22M | 0.3% |
+606,554
| New | +$4.22M |
|
|
FNCH
31
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $4.11M | 0.29% |
315,732
-9,268
| -3% | -$121K |
|
|
RCOR
32
DELISTED
Renovacor, Inc.
RCOR
| $4.01M | 0.28% |
442,902
+412,902
| +1,376% | +$3.74M |
|
33
Amicus Therapeutics
FOLD
$2.41B
| $3.95M | 0.28% |
414,174
+72,674
| +21% | +$694K |
|
34
MacroGenics
MGNX
$118M
| $3.95M | 0.28% |
188,478
-271,124
| -59% | -$5.68M |
|
35
Verastem
VSTM
$561M
| $3.78M | 0.27% |
1,227,371
-167,023
| -12% | -$514K |
|
36
Ovid Therapeutics
OVID
$93.2M
| $3.72M | 0.26% |
1,105,082
-19,790
| -2% | -$66.5K |
|
37
Lyra Therapeutics
LYRA
$11.8M
| $3.69M | 0.26% |
403,450
-221,234
| -35% | -$2.02M |
|
38
Corvus Pharmaceuticals
CRVS
$427M
| $3.67M | 0.26% |
757,545
+657,545
| +658% | +$3.18M |
|
|
AUTL
39
Autolus Therapeutics
AUTL
$383M
| $3.57M | 0.25% |
544,819
-811,229
| -60% | -$5.31M |
|
|
ISEE
40
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.52M | 0.25% |
+216,519
| New | +$3.52M |
|
41
NextCure
NXTC
$13.1M
| $3.43M | 0.24% |
509,155
-7,715
| -1% | -$52K |
|
|
IGMS
42
DELISTED
IGM Biosciences
IGMS
| $3.39M | 0.24% |
+51,500
| New | +$3.39M |
|
43
Clene
CLNN
$57.1M
| $3.34M | 0.24% |
489,321
+370,788
| +313% | +$2.53M |
|
|
ALLK
44
DELISTED
Allakos
ALLK
| $3.34M | 0.24% |
31,526
-174
| -0.5% | -$18.4K |
|
45
Protara Therapeutics
TARA
$124M
| $3.32M | 0.23% |
479,995
-104,809
| -18% | -$725K |
|
|
VINC
46
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $3.22M | 0.23% |
199,057
-227,686
| -53% | -$3.68M |
|
47
Phathom Pharmaceuticals
PHAT
$844M
| $3.2M | 0.23% |
99,560
-440
| -0.4% | -$14.1K |
|
|
CMMB
48
Chemomab Therapeutics
CMMB
$15.8M
| $3.16M | 0.22% |
285,264
-5,270
| -2% | -$58.4K |
|
49
Viking Therapeutics
VKTX
$3.03B
| $3.14M | 0.22% |
500,642
-24,112
| -5% | -$151K |
|
|
50
CRISPR Therapeutics
CRSP
$4.79B
| $3.13M | 0.22% |
27,968
-91,743
| -77% | -$10.3M |
|